Avantor® and BlueWhale Bio Partner to Accelerate CAR-T Manufacturing with Breakthrough Cell Activation and Expansion Technology
Rhea-AI Summary
Avantor (NYSE: AVTR) announced a strategic partnership with BlueWhale Bio on Oct 15, 2025 to accelerate CAR-T manufacturing by scaling production of Synecta™ cell-derived nanoparticles (CDNPs).
The collaboration combines Avantor's bioprocessing and GMP manufacturing capabilities with BlueWhale Bio's Synecta CDNP platform, aiming to produce GMP-grade CDNP materials to shorten CAR-T expansion time and increase manufacturing capacity.
BlueWhale Bio data cited earlier cell division, higher cell yields, and fewer process interventions, and notes Synecta T1 CDNPs are used in a 3-day CAR-T clinical trial.
Positive
- GMP-grade CDNP production partnership to support scale-up
- Synecta T1 CDNPs in a 3-day CAR-T clinical trial
- Preclinical/clinical data show earlier cell division and higher cell yields
Negative
- None.
News Market Reaction 25 Alerts
On the day this news was published, AVTR gained 6.42%, reflecting a notable positive market reaction. Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility. The stock closed at $14.76 on that trading session. This price movement added approximately $607M to the company's valuation, bringing the market cap to $10.06B at that time.
Data tracked by StockTitan Argus on the day of publication.
The partnership combines Avantor's bioprocessing and custom ancillary-reagent manufacturing capabilities with BlueWhale Bio's Synecta™ cell-derived nanoparticle (CDNP) platform, which mimics natural T-cell stimulation. The collaboration aims to accelerate CDNP manufacturing scale-up to help CAR-T developers significantly reduce expansion time - potentially expanding patient access and manufacturing capacity across the growing cell therapy sector. Together, the teams will produce GMP-grade CDNP materials to support this next-generation manufacturing approach.
"Our partnership with BlueWhale Bio reflects Avantor's commitment to delivering highly relevant manufacturing solutions to customers and enabling next-generation therapies through innovation, reliability, and scale," said Emmanuel Ligner, President and Chief Executive Officer of Avantor. "CAR-T therapies have transformed cancer care, but manufacturing remains a major bottleneck characterized by high cost, variability, and lengthy release cycles. The Avantor–BlueWhale Bio collaboration addresses these challenges by integrating next-generation activation and expansion reagents into a GMP-ready, scalable platform."
Data from BlueWhale Bio's preclinical and clinical programs demonstrate earlier cell division, higher cell yields, and fewer process interventions, indicating potential to reduce CAR-T process time and reduce cell stress during manufacturing. Synecta™ T1 CDNPs are used in a clinical trial using 3-day CAR-T manufacturing.
"BlueWhale Bio was founded to address the toughest manufacturing challenges in cell therapy. Failure to meet target dose levels in immune cell therapies can have a critical downstream impact on patients," said Peter Keller, Chief Executive Officer of BlueWhale Bio. "By partnering with Avantor, we're combining our novel Synecta™ platform with industrial-strength execution to accelerate the journey from discovery to delivery."
About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.
About BlueWhale Bio
BlueWhale Bio is dedicated to accelerating the growth and adoption of cell-based therapies by transforming the manufacturing process of immune cell therapy. The company is developing a portfolio of critical materials that bring the full benefits of higher-performing cell therapies to more patients faster and at lower costs. Its first product, Synecta™ T1, is used in a phase 1 clinical trial for a 3-day manufacturing process of an armored CAR-T. BlueWhale's innovations are based on cutting-edge discoveries in cell activation led by Dr. Carl June and Dr. Jim Riley at the University of
Avantor Media Contact
Eric Van Zanten
Head of External Communications
Avantor
610-529-6219
Eric.Vanzanten@avantorsciences.com
Avantor Investor Relations Contact
Allison Hosak
Senior Vice President, Global Communications
Avantor
908-329-7281
Allison.Hosak@avantorsciences.com
BlueWhale Bio Media Contact
Cammy Duong
cduong@bluewhale.bio
View original content:https://www.prnewswire.com/news-releases/avantor-and-bluewhale-bio-partner-to-accelerate-car-t-manufacturing-with-breakthrough-cell-activation-and-expansion-technology-302583953.html
SOURCE Avantor and Financial News
FAQ
What did Avantor (AVTR) announce on October 15, 2025 about CAR-T manufacturing?
How could the Avantor–BlueWhale Bio partnership affect CAR-T production timelines for AVTR investors?
Does the Avantor (AVTR) release disclose financial terms or timelines for the CDNP scale-up?
What evidence supports the Synecta platform mentioned in Avantor's AVTR partnership?
Will Avantor (AVTR) manufacture clinical-grade Synecta materials?
